Stock Price Quote

DR. REDDY'S LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE6449.0010.5 (+0.16 %)
PREV CLOSE ( ) 6438.50
OPEN PRICE ( ) 6438.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2517
TODAY'S LOW / HIGH ( )6387.30 6461.75
52 WK LOW / HIGH ( )4298.4 6494.95
NSE6449.608.85 (+0.14 %)
PREV CLOSE( ) 6440.75
OPEN PRICE ( ) 6416.00
BID PRICE (QTY) 6449.60 (140)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 193295
TODAY'S LOW / HIGH( ) 6385.25 6459.60
52 WK LOW / HIGH ( )4297 6494.05
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 24-02 1984
Management Info
K Satish Reddy - Chairman GV Prasad - Managing Director
Registered Office

Address 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040 - 4900 2900

Email mail@drreddys.com / shares@drreddys.com

Website www.drreddys.com

Registrars Details
Bigshare Services Pvt Ltd
306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad
Listing : BSE, NSE, MCX, New York

NEWS

26Feb Dr.Reddy's Laboratories informs about
Dr.Reddy's Laboratories has informed that the Company’s management will..
12Feb IRCTC, Hero MotoCorp and RITES to see
Indian Railways Catering and Tourism Corporation (IRCTC) has incorporate..
12Feb Dr. Reddy's trades higher on the BSE
Dr. Reddy's Laboratories is currently trading at Rs. 6259.85, up by 107...
10Feb Dr. Reddy's gets EIR from USFDA for fo
Dr. Reddy's Laboratories has received Establishment Inspection Report (E..
31Jan Dr. Reddy’s Laboratories informs about
Pursuant to Regulation 30 of the Securities and Exchange Board of India..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit475226128
Gross Profit 6319 38660
Operating Profit 883948061
Net Sales 41030169625

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  28639.35 (0.55%)
M.Cap ( in Cr)60856.62
Bharat Parenterals (BSE)
peergroup  1147.65 (10.28%)
M.Cap ( in Cr)667.89
Astrazeneca Pharma I (BSE)
peergroup  5567.65 (1.95%)
M.Cap ( in Cr)13919.13
Neuland Laboratories (BSE)
peergroup  7063.75 (1.37%)
M.Cap ( in Cr)9062.71
Mankind Pharma (BSE)
peergroup  2097.55 (1.58%)
M.Cap ( in Cr)84025.43

Shareholding Pattern

MUTUAL FUNDS/UTI 8.22%
FI/BANKS/INSURANCE 7.99%
PROMOTERS 26.65%
NON-INSTITUTION 10.75%
GOVERNMENT 0%
FII 0%

About Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 6449. Its current market capitalisation stands at Rs 107577.8 Cr. In the latest quarter, company has reported Gross Sales of Rs. 169625 Cr and Total Income of Rs.175538 Cr. The company's management includes Alpna Hansraj Seth, Claudio Albrecht, Shikha Sharma, Leo Puri, Arun Kumar, Penny Wan, KP Krishnan, Kalpana Morparia, GV Prasad, K Satish Reddy, K Randhir Singh.

It is listed on the BSE with a BSE Code of 500124 , NSE with an NSE Symbol of DRREDDY and ISIN of INE089A01023. It's Registered office is at 8-2-337,Road No. 3,Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are A Rama Chandra Rao & Co, Bharat S Raut & Co, BSR & Co, BSR & Co LLP, SR Batliboi & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.